COMMUNIQUÉS West-GlobeNewswire

Aeglea BioTherapeutics to Present at UBS Global Healthcare Conference
15/05/2018
Company to Webcast Presentation on Tuesday, May 22 at 8:30 a.m. ET AUSTIN, Texas, May 15, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a clinical-stage biotechnology company that designs and [...]
Neos Therapeutics to Present at the UBS Global Healthcare Conference
15/05/2018
DALLAS and FORT WORTH, Texas, May 15, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS ), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) [...]
Daré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive Candidate
15/05/2018
SAN DIEGO, May 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today the initiation of [...]
EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis
15/05/2018
Study demonstrates no evidence of QTc prolongation EndoLogic remains on plan to initiate 12-week renzapride Phase 2 trial pending collaboration with a development partner CLIFTON, N.J., May 15, 2018 (GLOBE NEWSWIRE) -- [...]
SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial Results
15/05/2018
SAN RAMON, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY ), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with [...]
Fortress Biotech Appoints Michael G. King, Jr. as Entrepreneur in Residence
15/05/2018
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO ) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]
Cambrex Completes Pilot Plant Expansion at its High Point, NC Facility
15/05/2018
Work Underway on New $24 Million High Potency Plant at Charles City, Iowa EAST RUTHERFORD, N.J., May 15, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM ), the leading manufacturer of small molecule innovator [...]
Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage
15/05/2018
Routine Safety Monitoring Committee Review Confirmed No Dose Reductions Necessary ROCKVILLE, Md., May 15, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical-stage biopharmaceutical [...]
MimiVax to Present Interim Phase II Trial Data on Multi-focal Immunotherapy SurVaxM for the Treatment of Glioblastoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
15/05/2018
BUFFALO, N.Y., May 15, 2018 (GLOBE NEWSWIRE) -- MimiVax LLC, a clinical-stage biotechnology company developing immunotherapeutics and targeted therapies for cancer treatment, today announced that interim results from a [...]
CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting
15/05/2018
ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, [...]
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments
15/05/2018
Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA) Annual Meeting [...]
Adherium to Present at the Chardan Digital Health Conference on Tuesday, May 22, 2018
15/05/2018
SAN MATEO, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), an award-winning digital health company that improves medication adherence and patient outcomes, today announced the Company will be participating [...]
Interpace Diagnostics Group Reports First Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
15/05/2018
Revenue Grew 39% Over the Prior Year’s Quarter and 10% Over the Prior Period Record Quarterly Revenue of $4.8 Million and Record Quarterly Cash Receipts of $4.4 Million Cash & Cash Equivalents Remain Strong at $12.6 [...]
Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial
15/05/2018
PENNVAX®-GP generated among highest levels of immune responses ever demonstrated in a human HIV vaccine study PLYMOUTH MEETING, Pa., May 15, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) today [...]
Progressive Care Inc. Reports Largest Single Revenue Quarter in Company History
15/05/2018
Florida-Based Healthcare, Technology and Tele-Pharmacy Services Provider Shows 24% Increase in Prescriptions Filled Reports March 2018 Revenue of $1.9M as Largest Single Month in Company History MIAMI, May 15, 2018 ( [...]
Emerald Health Therapeutics Announces $16.8 Million Prospectus Sale; Concurrent Secondary Sale
15/05/2018
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VICTORIA, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) ("Emerald" or [...]
Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018
15/05/2018
FRAMINGHAM, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a [...]
Affimed Reports Financial Results for First Quarter 2018
15/05/2018
Heidelberg, Germany, May 15, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results [...]
Trading by management and close relations of management
15/05/2018
Read the full announcement in the attached file Attachment 2018_32_Trading_by_management_EN

Pages